Patents by Inventor Francois Brucelle

Francois Brucelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P300/CBP HAT INHIBITORS
    Publication number: 20250230137
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Application
    Filed: August 29, 2024
    Publication date: July 17, 2025
    Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
  • BRD9 degraders and uses thereof
    Patent number: 11787800
    Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: October 17, 2023
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Sabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe, Johannes H. Voigt, Matthew Netherton, Francois Brucelle
  • Methods and compounds for treating disorders
    Patent number: 11773085
    Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Qianhe Zhou, Michael Bocker, David Simon Millan, Ho Man Chan, Luis Soares, Matthew Russell Netherton, Sabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe, Francois Brucelle
  • LSD1 inhibitors and medical uses thereof
    Patent number: 11547695
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 10, 2023
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS
    Publication number: 20220331304
    Abstract: Provided are methods for treating neurological disorders using compounds of Formula (I), and pharmaceutically acceptable salts and compositions thereof.
    Type: Application
    Filed: July 29, 2020
    Publication date: October 20, 2022
    Inventors: Francois Brucelle, Julian R. Levell, Jonathan E. Wilson
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20220079917
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: April 27, 2021
    Publication date: March 17, 2022
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • P300/CBP HAT inhibitors
    Patent number: 11274090
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 15, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
  • LSD1 inhibitors and medical uses thereof
    Patent number: 11013718
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 25, 2021
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • P300/CBP HAT INHIBITORS
    Publication number: 20210115008
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Application
    Filed: February 15, 2019
    Publication date: April 22, 2021
    Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
  • METHODS AND COMPOUNDS FOR TREATING DISORDERS
    Publication number: 20210009568
    Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.
    Type: Application
    Filed: July 29, 2020
    Publication date: January 14, 2021
    Inventors: Qianhe Zhou, Michael Bocker, David Simon Millan, Ho Man Chan, Luis Soares, Matthew Russell Netherton, Sabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe, Francois Brucelle
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20200306223
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: November 1, 2019
    Publication date: October 1, 2020
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • LSD1 inhibitors and medical uses thereof
    Patent number: 10517849
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 31, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20190274998
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 12, 2019
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna